LEGN
Legend Biotech Corp
NASDAQ · Healthcare · Biotechnology · US
$19.27
−3.21%Price chart
Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10
ValuationView details →
P/E (Fwd)
42.0x
EV/EBITDA
−422.6x
Market Cap
$3.75B
MomentumView details →
1D Return
−3.21%
YTD Return
−11.73%
RSI (14)
38.0
ValuationView details →
P/E (Fwd)
42.0x
EV/EBITDA
−422.6x
Market Cap
$3.75B
RSI (14)
38.0
MomentumView details →
1D Return
−3.21%
YTD Return
−11.73%
SummaryUpdated Jun 1, 2026
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey. The company is a subsidiary of Genscript Biotech Corporation and went public in June 2020. Legend Biotech specializes in developing innovative cell therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating various cancers and other diseases. The company has achieved significant commercial success with its lead product CARVYKTI, which has become a leading treatment for multiple myeloma, and continues to expand its pipeline of cell therapy candidates targeting both blood cancers and solid tumors.
Similar companies
Latest newsMore news →
Legend Biotech reported second-quarter 2026 results, achieving its first quarter of company-wide profitability on both IFRS and adjusted basis, with continued global growth for CARVYKTI.30d agoK2 Therapeutics appointed Huang Ying, former CEO of Legend Biotech, as its new CEO.30d agoYing Huang stepped down as Chief Executive Officer and board member of Legend Biotech, effective July 24, 2026.45d ago